Dr. Jeremy Davis is a surgical oncologist and Associate Research Physician in the Center for Cancer Research at the National Cancer Institute, part of the Intramural Research Program of the National Institutes of Health. Dr. Davis was trained in General Surgery and dedicated three years of post-graduate training in cancer research at NCI. Later, he completed a clinical fellowship in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center. He joined the NCI in 2015 to establish a gastric cancer research program with a focus on CDH1-driven diffuse-type gastric cancers. Dr. Davis is the principal investigator of multiple investigator-initiated clinical trials. He has published extensively on the clinical and molecular features of hereditary diffuse gastric and lobular breast cancers. His major contributions to the field include descriptions of phenotypic variability among CDH1 variant carriers, the effective application of gastric surveillance as a viable alternative to prophylactic total gastrectomy, and the long-term consequences of surgery for prevention of cancer. In addition, his research has demonstrated the unique molecular phenotype of signet ring cell precancers and established patient-centered cancer risk estimates stratified by family cancer history. In addition to his clinical and research activities, Dr. Davis directed the NCI Surgical Oncology Research Fellowship from 2016 to 2020, and from 2018 to 2023 served as Surgeon-in-Chief of “America’s Research Hospital”, the NIH Clinical Center.